Primary regulatory
FDA Approves Ozempic (Semaglutide) for Type 2 Diabetes
FDA approval of Ozempic (semaglutide) injection for Type 2 diabetes, NDA 209637.
U.S. Food and Drug AdministrationPublished 2017-12-05Accessed 2026-07-01
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
fda-ozempic-approval-2017
Source usage
Linked from 8 pages
Compound
Semaglutide
ComparisonTirzepatide vs Semaglutide
Evidence curationBest Peptides for Weight Loss
GuideCompounded GLP-1 Regulation: What Changed and What to Check
GuideFDA Enforcement Timeline: Major Actions on Peptides and Compounding
GuidePeptide Category Explainers: How Every Compound Class on This Site Is Defined
GuidePeptide Half-Life Reference Table
Research hubCompounded Peptides Explained: 503A vs 503B
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.